Scientists move closer to improved anthrax vaccine
September 5th, 2009 - 2:33 pm ICT by ANI ( Leave a comment )Washington, Sept 5 (ANI): Scientists from Albert Einstein College of Medicine of Yeshiva University have discovered two small protein fragments that could lead to improved anthrax vaccine with less side effects.
The current anthrax vaccine is intended mainly for members of the armed forces serving in areas considered high risk and for individuals involved in homeland biosecurity.
“Our research was motivated by the fact that the current anthrax vaccine has significant limitations and there is great need for a better one,” said lead author Nareen Abboud, an Einstein postdoctoral fellow and lead author of the study.
Anthrax results in part from toxic proteins, or toxins, that the multiplying bacteria secrete. The current anthrax vaccine employs one of these proteins, which elicits protective antibodies when injected into people.
While this 40-year-old vaccine can prevent disease, it has significant drawbacks. Immunity is temporary, and five injections over the course of 18 months are needed to sustain it.
One in five vaccine recipients develop redness, swelling or pain at the injection site, and a small number develop severe allergic reactions.
During the study, scientists focused on the protein toxin used in the current vaccine, looking for the smallest protein sections (known as peptides) that could trigger the production of protective antibodies when injected into animals.
They injected the current vaccine into mice and recovered six different “pure” strains of antibodies known as monoclonal antibodies.
They then mixed each type of antibody with the 145 peptides formed by chopping up the vaccine protein.
Ultimately, the researchers found that two of the 145 peptides fit the bill: Each peptide elicited antibodies when injected into mice, and these antibodies protected macrophages from death that would normally have occurred when the macrophages were exposed to anthrax toxin.
The next step in the Einstein research will be to inject the peptides into an animal model to see if the peptides can protect against anthrax infection.
“We’re hopeful that the two peptides that we have identified in this study can offer these benefits,” said Abboud.
The study appears in The Journal of Biological Chemistry. (ANI)
- Anthrax shot protects simians from lethal infection - Jan 13, 2012
- Vaccine made with synthetic gene shows promise against pneumonia - Feb 22, 2011
- Promising target for AIDS vaccine identified - Apr 01, 2011
- Edible vaccine for malaria on way - Dec 31, 2010
- TB shot found promising in animal tests - Sep 05, 2011
- Universal influenza vaccine 'on the anvil' - Dec 07, 2010
- Novel vaccine that produces strong immunity against cocaine high created - Jan 05, 2011
- World's first plastic antibodies created - Jun 22, 2010
- Soon, nasal spray vaccine to fight Alzheimer's, stroke - Mar 01, 2011
- Oral vaccines are 'alternative to jab' - Feb 11, 2011
- Will a female birth control vaccine work? - Mar 13, 2011
- Vaccine-delivering nanoparticles may help fight HIV, malaria - Feb 23, 2011
- New medical weapons against anthrax attacks - Jun 24, 2010
- H1N1 pandemic flu strain 'key to universal vaccine' - Jan 11, 2011
- Novel immune therapy for pancreatic cancer discovered - Mar 25, 2011
Tags: abboud, albert einstein, albert einstein college, albert einstein college of medicine, albert einstein college of medicine of yeshiva universi, allergic reactions, anthrax toxin, anthrax vaccine, college of medicine, einstein college of medicine, high risk, macrophages, monoclonal antibodies, peptides, postdoctoral fellow, protective antibodies, protein fragments, protein toxin, toxic proteins, vaccine recipients
